A member of the 

​​​​​Reengineering Medicines Development

Cutting development time and cost, to bring affordable medicines to patients more quickly 

​

Developing new medicines is lengthy, costly and high risk. This development process drives up prices of new medicines and reduces access, delaying the introduction of importance new therapies.  

Vermilion Life Sciences takes a different approach. We Reengineer Medicines Development to improve regulatory pathways and reduce development times and costs. We build partnerships between companies, regulators, payers and patients to improve the value of new medicines and speed adoption making them available more quickly, at lower cost with greater certainty in use. ​ 

​

As a member of the UK Government's Office for Life Sciences Expert Advisory Group on Innovative Medicines, and leading a work stream on the Accelerated Access Review, (Final report published here) we showed how all parties working together has the potential to improve development efficiency and effectiveness, to speed decision making and access to new medicines.

Please contact us to see how we can cut your development costs and time while improving the likelihood of access.

Click the links to read Scrip's review of Reengineering Medicines Development;

'R&D revolution could secure good, affordable prices'

and Deloitte's 'Focus on Life Sciences'  article.

​

Vermilion Life Sciences: Reengineering Medicines Development #ReMedDev®

Please explore the links above to read more about Vermilion Life Sciences.

Download an auto ​updating 

​version of this site on

​Copyright
© 2014 - 2018

ReMedDev® is a TM of

Vermilion Life Sciences Ltd

Follow us

Registered Address